Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Liquidia CorporationNASDAQ: LQDA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $88.39M, compared with -$35.64M a year earlier. Trailing-twelve-month EBITDA was $177.83M.
Context
- EBITDA amounted to 27.3% of revenue in FY2025, down 799.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $20.15M (+146.6%) for the fiscal year ending Dec 2026, a step up from the +62.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $88.39M+38.6% QoQ
- Last fiscal yearDec 2025
- -$43.22M+62.6% YoY
- LTMJun 2026
- $177.83M+245.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +348.0% | +2784.7% | +2436.7 pp |
| 1 year | +62.6% | +146.6% | +84.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (43.22M) USD
- Year-over-year change
- +62.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (43.22M) | +62.6% |
| FY2024 | 2024-12-31 | (115.71M) | -65.2% |
| FY2023 | 2023-12-31 | (70.05M) | -100.0% |
| FY2022 | 2022-12-31 | (35.03M) | -24.2% |
| FY2021 | 2021-12-31 | (28.21M) | — |
EBITDA vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +245.9% is the highest of 4, against a peer median of -2.3%.
- EBITDA amounts to 39.4% of revenue for LQDA, versus a peer median of 67.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.68B USD | -2.3% | +20.5% | 53.1% | |
| LTM Jun 2026 | $177.83M USD | +245.9% | — | 39.4% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | -SEK 248.71M SEK | -24.2% | — | 18700.4% |
| LTM Jun 2026 | -$770.76M USD | +17.8% | — | 67.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LQDA) | — | -2.3% | +20.5% | 67.8% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.85M | 15.94M | 17.49M | 14M | 158.32M |
| Cost of Revenue | 3.02M | 2.86M | 2.89M | 5.88M | 13.24M |
| Gross Profit | 9.83M | 13.08M | 14.6M | 8.12M | 145.08M |
| Gross Margin | 76.5% | 82.1% | 83.5% | 58.0% | 91.6% |
| Research & Development | 20.52M | 19.44M | 43.24M | 47.84M | 39.28M |
| Selling, General & Admin | 23.11M | 32.41M | 44.74M | 81.57M | 157.18M |
| Operating Expenses | 43.63M | 51.85M | 87.98M | 129.41M | 196.45M |
| Depreciation & Amortization | 5.61M | 3.65M | 2.18M | 2.2M | 1.53M |
| EBITDA | (28.21M) | (35.03M) | (70.05M) | (115.71M) | (43.22M) |
| EBITDA Margin | -219.4% | -219.8% | -400.6% | -826.7% | -27.3% |
| Operating Income | (33.8M) | (38.77M) | (73.38M) | (121.29M) | (51.38M) |
| Operating Margin | -263.0% | -243.3% | -419.6% | -866.6% | -32.5% |
| Interest Income | 33K | 1.09M | 3.47M | 7.65M | 6.62M |
| Interest Expense | 762K | 2.34M | 6.27M | 12.49M | 24.17M |
| Other Income / Expenses | (782K) | (2.25M) | (5.12M) | (9.1M) | (17.55M) |
| Income Before Tax | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Pre-Tax Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Net Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| EPS (Basic) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| EPS (Diluted) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| Weighted Avg Shares | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
| Weighted Avg Shares (Diluted) | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.